Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management

"As a co-author of this systematic review and an academic and researcher who utilized MolecuLight's technology in practice, I can attest to the profound impact it has on clinicians' ability to manage complex wounds," said study author Rosemarie Derwin, PhD, MSc, PG Dip, BNS, RGN, RNT, experienced nurse, educator, and researcher at the School of Nursing and Midwifery, Trinity College Dublin. "The real-time visualization of bacteria provides immediate practical information that guides treatment decisions, leading to more effective care plans and ultimately, better outcomes for patients. This study affirms what many of us have seen clinically: MolecuLight is a vital asset in modern wound care."

"As a co-author of this systematic review and an academic and researcher who utilized MolecuLight's technology in practice, I can attest to the profound impact it has on clinicians' ability to manage complex wounds," said study author Rosemarie Derwin, PhD, MSc, PG Dip, BNS, RGN, RNT, experienced nurse, educator, and researcher at the School of Nursing and Midwifery, Trinity College Dublin. "The real-time visualization of bacteria provides immediate practical information that guides treatment decisions, leading to more effective care plans and ultimately, better outcomes for patients. This study affirms what many of us have seen clinically: MolecuLight is a vital asset in modern wound care."

This detailed systematic review of current evidence underscores the capability of MolecuLight devices to identify clinically significant levels of bioburden. This bioburden, frequently undetectable via visual inspection and present in over 80% of chronic wounds,² frequently causes infection and necessitates targeted intervention. By visualizing bacterial fluorescence, clinicians are equipped to:

MolecuLight continues to build on a robust foundation of clinical evidence. With over 100 peer-reviewed publications demonstrating the utility and impact of its fluorescence imaging technology, this systematic review powerfully reinforces that managing bacterial burden is essential for effective wound care. It affirms that MolecuLight devices provide an invaluable and proven tool for clinicians to achieve this, by enabling more precise and targeted interventions that hold strong promise for improved healing trajectories and enhanced patient quality of life. The company remains dedicated to advancing wound care through innovative solutions that improve patient lives and reduce healthcare costs.

About MolecuLight Inc.
MolecuLight Inc. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only Class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

 

Photo - https://mma.prnewswire.com/media/2719217/MolecuLight_Landmark_Study_Affirms%C2%A0MolecuLight_s_Efficacy_in_Rea.jpg 
Photo - https://mma.prnewswire.com/media/2719216/MolecuLight_Landmark_Study_Affirms%C2%A0MolecuLight_s_Efficacy_in_Rea.jpg 

For sales, media or other inquiries or further information, please contact: MolecuLight Inc., Danielle Dunham, Director of Marketing and Product Management, T. +1.416.542.5524, [email protected], www.moleculight.com

 

View original content:https://www.prnewswire.co.uk/news-releases/landmark-study-affirms-moleculights-efficacy-in-real-time-bacterial-detection-for-improved-wound-management-302491528.html